Source comparison
Reading the Numbers Honestly: The Full Comparison
With the evidence caveats in place, the attribute-by-attribute comparison below summarizes the documented facts for each peptide. Every cell reflects the cited sources; where something is not established, the table says so rather than guessing. Class Stabilize
This comparison does not assign a generated winner or score.
- With the evidence caveats in place, the attribute-by-attribute comparison below summarizes the documented facts for each peptide. Every cell reflects the cited sources; where something is not established, the table says so rather than guessing.
- Class
- Stabilized synthetic GHRH(1–44) analog (trans-3-hexenoyl group resists DPP-4 cleavage)
- Synthetic GHRH(1–29) — shortest N-terminal fragment with full activity
- Mechanism
- GHRH-receptor agonist → pulsatile endogenous GH release → ↑ IGF-1
- Primary studied use
- Reduction of excess visceral fat in HIV-associated lipodystrophy
- Diagnostic GH-secretion test; pediatric idiopathic GH deficiency
- Highest evidence tier
- FDA-approved + multiple Phase 3 double-blind, placebo-controlled RCTs[1][2]
- Human but older/limited; mainly pediatric GHD; no modern adult RCT[5]
- Typical route
- Subcutaneous injection, once daily
- Subcutaneous (treatment) or intravenous (single-dose diagnostic)
- Half-life
- ~18 min (single dose); ~37 min (multiple doses)[9]
- ~10–20 min in humans[6]
- Reference dosing (research settings only)
- Clinical label: 2 mg SC daily (HIV lipodystrophy)
- Historic clinical: ~30 µg/kg/day SC (pediatric GHD); 1 µg/kg IV diagnostic
- FDA status
- Approved 2010 (Egrifta) — the only GHRH analog with a current indication
- Approved 1997 (Geref); withdrawn 2008 for commercial (not safety/efficacy) reasons; no current approved product[10]
- Sport status
- WADA-prohibited (GHRH analog)[8]
- Direct head-to-head trial
- None — no published RCT compares the two